Medical Care
Global Long Chain Modified Peptide Drugs Market Research Report 2025
- May 12, 25
- ID: 235071
- Pages: 83
- Figures: 89
- Views: 9
The global market for Long Chain Modified Peptide Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Long Chain Modified Peptide Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Long Chain Modified Peptide Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Long Chain Modified Peptide Drugs in Intravenous Injection is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Long Chain Modified Peptide Drugs include Novartis, Merck Serono, Ferring Pharmaceuticals, lpsen PHarma Biotech, Lilly, AstraZeneca, SciClone Pharmaceuticals, Sinopep Allsino Bio Pharmaceutical, Takeda, Roche, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Long Chain Modified Peptide Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long Chain Modified Peptide Drugs.
The Long Chain Modified Peptide Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Long Chain Modified Peptide Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long Chain Modified Peptide Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Merck Serono
Ferring Pharmaceuticals
lpsen PHarma Biotech
Lilly
AstraZeneca
SciClone Pharmaceuticals
Sinopep Allsino Bio Pharmaceutical
Takeda
Roche
Sanofi
Ambio Pharmaceuticals
Segment by Type
Hormone Peptide Drugs
Immunomodulatory Peptide Drugs
Vasoactive Peptide Drugs
Others
Segment by Application
Intravenous Injection
Intramuscular Injection
Hypodermic Injection
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long Chain Modified Peptide Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
North American market for Long Chain Modified Peptide Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Long Chain Modified Peptide Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Long Chain Modified Peptide Drugs in Intravenous Injection is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Long Chain Modified Peptide Drugs include Novartis, Merck Serono, Ferring Pharmaceuticals, lpsen PHarma Biotech, Lilly, AstraZeneca, SciClone Pharmaceuticals, Sinopep Allsino Bio Pharmaceutical, Takeda, Roche, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Long Chain Modified Peptide Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long Chain Modified Peptide Drugs.
The Long Chain Modified Peptide Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Long Chain Modified Peptide Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long Chain Modified Peptide Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Merck Serono
Ferring Pharmaceuticals
lpsen PHarma Biotech
Lilly
AstraZeneca
SciClone Pharmaceuticals
Sinopep Allsino Bio Pharmaceutical
Takeda
Roche
Sanofi
Ambio Pharmaceuticals
Segment by Type
Hormone Peptide Drugs
Immunomodulatory Peptide Drugs
Vasoactive Peptide Drugs
Others
Segment by Application
Intravenous Injection
Intramuscular Injection
Hypodermic Injection
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long Chain Modified Peptide Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long Chain Modified Peptide Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Hormone Peptide Drugs
1.2.3 Immunomodulatory Peptide Drugs
1.2.4 Vasoactive Peptide Drugs
1.2.5 Others
1.3 Market by Application
1.3.1 Global Long Chain Modified Peptide Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Intravenous Injection
1.3.3 Intramuscular Injection
1.3.4 Hypodermic Injection
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Long Chain Modified Peptide Drugs Market Perspective (2020-2031)
2.2 Global Long Chain Modified Peptide Drugs Growth Trends by Region
2.2.1 Global Long Chain Modified Peptide Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Long Chain Modified Peptide Drugs Historic Market Size by Region (2020-2025)
2.2.3 Long Chain Modified Peptide Drugs Forecasted Market Size by Region (2026-2031)
2.3 Long Chain Modified Peptide Drugs Market Dynamics
2.3.1 Long Chain Modified Peptide Drugs Industry Trends
2.3.2 Long Chain Modified Peptide Drugs Market Drivers
2.3.3 Long Chain Modified Peptide Drugs Market Challenges
2.3.4 Long Chain Modified Peptide Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Long Chain Modified Peptide Drugs Players by Revenue
3.1.1 Global Top Long Chain Modified Peptide Drugs Players by Revenue (2020-2025)
3.1.2 Global Long Chain Modified Peptide Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Long Chain Modified Peptide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Long Chain Modified Peptide Drugs Revenue
3.4 Global Long Chain Modified Peptide Drugs Market Concentration Ratio
3.4.1 Global Long Chain Modified Peptide Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long Chain Modified Peptide Drugs Revenue in 2024
3.5 Global Key Players of Long Chain Modified Peptide Drugs Head office and Area Served
3.6 Global Key Players of Long Chain Modified Peptide Drugs, Product and Application
3.7 Global Key Players of Long Chain Modified Peptide Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Long Chain Modified Peptide Drugs Breakdown Data by Type
4.1 Global Long Chain Modified Peptide Drugs Historic Market Size by Type (2020-2025)
4.2 Global Long Chain Modified Peptide Drugs Forecasted Market Size by Type (2026-2031)
5 Long Chain Modified Peptide Drugs Breakdown Data by Application
5.1 Global Long Chain Modified Peptide Drugs Historic Market Size by Application (2020-2025)
5.2 Global Long Chain Modified Peptide Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Long Chain Modified Peptide Drugs Market Size (2020-2031)
6.2 North America Long Chain Modified Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Long Chain Modified Peptide Drugs Market Size by Country (2020-2025)
6.4 North America Long Chain Modified Peptide Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Long Chain Modified Peptide Drugs Market Size (2020-2031)
7.2 Europe Long Chain Modified Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Long Chain Modified Peptide Drugs Market Size by Country (2020-2025)
7.4 Europe Long Chain Modified Peptide Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Long Chain Modified Peptide Drugs Market Size (2020-2031)
8.2 Asia-Pacific Long Chain Modified Peptide Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Long Chain Modified Peptide Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Long Chain Modified Peptide Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Long Chain Modified Peptide Drugs Market Size (2020-2031)
9.2 Latin America Long Chain Modified Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Long Chain Modified Peptide Drugs Market Size by Country (2020-2025)
9.4 Latin America Long Chain Modified Peptide Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Long Chain Modified Peptide Drugs Market Size (2020-2031)
10.2 Middle East & Africa Long Chain Modified Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Long Chain Modified Peptide Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Long Chain Modified Peptide Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Long Chain Modified Peptide Drugs Introduction
11.1.4 Novartis Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.1.5 Novartis Recent Development
11.2 Merck Serono
11.2.1 Merck Serono Company Details
11.2.2 Merck Serono Business Overview
11.2.3 Merck Serono Long Chain Modified Peptide Drugs Introduction
11.2.4 Merck Serono Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.2.5 Merck Serono Recent Development
11.3 Ferring Pharmaceuticals
11.3.1 Ferring Pharmaceuticals Company Details
11.3.2 Ferring Pharmaceuticals Business Overview
11.3.3 Ferring Pharmaceuticals Long Chain Modified Peptide Drugs Introduction
11.3.4 Ferring Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.3.5 Ferring Pharmaceuticals Recent Development
11.4 lpsen PHarma Biotech
11.4.1 lpsen PHarma Biotech Company Details
11.4.2 lpsen PHarma Biotech Business Overview
11.4.3 lpsen PHarma Biotech Long Chain Modified Peptide Drugs Introduction
11.4.4 lpsen PHarma Biotech Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.4.5 lpsen PHarma Biotech Recent Development
11.5 Lilly
11.5.1 Lilly Company Details
11.5.2 Lilly Business Overview
11.5.3 Lilly Long Chain Modified Peptide Drugs Introduction
11.5.4 Lilly Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.5.5 Lilly Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Details
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Long Chain Modified Peptide Drugs Introduction
11.6.4 AstraZeneca Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.6.5 AstraZeneca Recent Development
11.7 SciClone Pharmaceuticals
11.7.1 SciClone Pharmaceuticals Company Details
11.7.2 SciClone Pharmaceuticals Business Overview
11.7.3 SciClone Pharmaceuticals Long Chain Modified Peptide Drugs Introduction
11.7.4 SciClone Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.7.5 SciClone Pharmaceuticals Recent Development
11.8 Sinopep Allsino Bio Pharmaceutical
11.8.1 Sinopep Allsino Bio Pharmaceutical Company Details
11.8.2 Sinopep Allsino Bio Pharmaceutical Business Overview
11.8.3 Sinopep Allsino Bio Pharmaceutical Long Chain Modified Peptide Drugs Introduction
11.8.4 Sinopep Allsino Bio Pharmaceutical Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.8.5 Sinopep Allsino Bio Pharmaceutical Recent Development
11.9 Takeda
11.9.1 Takeda Company Details
11.9.2 Takeda Business Overview
11.9.3 Takeda Long Chain Modified Peptide Drugs Introduction
11.9.4 Takeda Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.9.5 Takeda Recent Development
11.10 Roche
11.10.1 Roche Company Details
11.10.2 Roche Business Overview
11.10.3 Roche Long Chain Modified Peptide Drugs Introduction
11.10.4 Roche Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.10.5 Roche Recent Development
11.11 Sanofi
11.11.1 Sanofi Company Details
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Long Chain Modified Peptide Drugs Introduction
11.11.4 Sanofi Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.11.5 Sanofi Recent Development
11.12 Ambio Pharmaceuticals
11.12.1 Ambio Pharmaceuticals Company Details
11.12.2 Ambio Pharmaceuticals Business Overview
11.12.3 Ambio Pharmaceuticals Long Chain Modified Peptide Drugs Introduction
11.12.4 Ambio Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.12.5 Ambio Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long Chain Modified Peptide Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Hormone Peptide Drugs
1.2.3 Immunomodulatory Peptide Drugs
1.2.4 Vasoactive Peptide Drugs
1.2.5 Others
1.3 Market by Application
1.3.1 Global Long Chain Modified Peptide Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Intravenous Injection
1.3.3 Intramuscular Injection
1.3.4 Hypodermic Injection
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Long Chain Modified Peptide Drugs Market Perspective (2020-2031)
2.2 Global Long Chain Modified Peptide Drugs Growth Trends by Region
2.2.1 Global Long Chain Modified Peptide Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Long Chain Modified Peptide Drugs Historic Market Size by Region (2020-2025)
2.2.3 Long Chain Modified Peptide Drugs Forecasted Market Size by Region (2026-2031)
2.3 Long Chain Modified Peptide Drugs Market Dynamics
2.3.1 Long Chain Modified Peptide Drugs Industry Trends
2.3.2 Long Chain Modified Peptide Drugs Market Drivers
2.3.3 Long Chain Modified Peptide Drugs Market Challenges
2.3.4 Long Chain Modified Peptide Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Long Chain Modified Peptide Drugs Players by Revenue
3.1.1 Global Top Long Chain Modified Peptide Drugs Players by Revenue (2020-2025)
3.1.2 Global Long Chain Modified Peptide Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Long Chain Modified Peptide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Long Chain Modified Peptide Drugs Revenue
3.4 Global Long Chain Modified Peptide Drugs Market Concentration Ratio
3.4.1 Global Long Chain Modified Peptide Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long Chain Modified Peptide Drugs Revenue in 2024
3.5 Global Key Players of Long Chain Modified Peptide Drugs Head office and Area Served
3.6 Global Key Players of Long Chain Modified Peptide Drugs, Product and Application
3.7 Global Key Players of Long Chain Modified Peptide Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Long Chain Modified Peptide Drugs Breakdown Data by Type
4.1 Global Long Chain Modified Peptide Drugs Historic Market Size by Type (2020-2025)
4.2 Global Long Chain Modified Peptide Drugs Forecasted Market Size by Type (2026-2031)
5 Long Chain Modified Peptide Drugs Breakdown Data by Application
5.1 Global Long Chain Modified Peptide Drugs Historic Market Size by Application (2020-2025)
5.2 Global Long Chain Modified Peptide Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Long Chain Modified Peptide Drugs Market Size (2020-2031)
6.2 North America Long Chain Modified Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Long Chain Modified Peptide Drugs Market Size by Country (2020-2025)
6.4 North America Long Chain Modified Peptide Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Long Chain Modified Peptide Drugs Market Size (2020-2031)
7.2 Europe Long Chain Modified Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Long Chain Modified Peptide Drugs Market Size by Country (2020-2025)
7.4 Europe Long Chain Modified Peptide Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Long Chain Modified Peptide Drugs Market Size (2020-2031)
8.2 Asia-Pacific Long Chain Modified Peptide Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Long Chain Modified Peptide Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Long Chain Modified Peptide Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Long Chain Modified Peptide Drugs Market Size (2020-2031)
9.2 Latin America Long Chain Modified Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Long Chain Modified Peptide Drugs Market Size by Country (2020-2025)
9.4 Latin America Long Chain Modified Peptide Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Long Chain Modified Peptide Drugs Market Size (2020-2031)
10.2 Middle East & Africa Long Chain Modified Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Long Chain Modified Peptide Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Long Chain Modified Peptide Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Long Chain Modified Peptide Drugs Introduction
11.1.4 Novartis Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.1.5 Novartis Recent Development
11.2 Merck Serono
11.2.1 Merck Serono Company Details
11.2.2 Merck Serono Business Overview
11.2.3 Merck Serono Long Chain Modified Peptide Drugs Introduction
11.2.4 Merck Serono Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.2.5 Merck Serono Recent Development
11.3 Ferring Pharmaceuticals
11.3.1 Ferring Pharmaceuticals Company Details
11.3.2 Ferring Pharmaceuticals Business Overview
11.3.3 Ferring Pharmaceuticals Long Chain Modified Peptide Drugs Introduction
11.3.4 Ferring Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.3.5 Ferring Pharmaceuticals Recent Development
11.4 lpsen PHarma Biotech
11.4.1 lpsen PHarma Biotech Company Details
11.4.2 lpsen PHarma Biotech Business Overview
11.4.3 lpsen PHarma Biotech Long Chain Modified Peptide Drugs Introduction
11.4.4 lpsen PHarma Biotech Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.4.5 lpsen PHarma Biotech Recent Development
11.5 Lilly
11.5.1 Lilly Company Details
11.5.2 Lilly Business Overview
11.5.3 Lilly Long Chain Modified Peptide Drugs Introduction
11.5.4 Lilly Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.5.5 Lilly Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Details
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Long Chain Modified Peptide Drugs Introduction
11.6.4 AstraZeneca Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.6.5 AstraZeneca Recent Development
11.7 SciClone Pharmaceuticals
11.7.1 SciClone Pharmaceuticals Company Details
11.7.2 SciClone Pharmaceuticals Business Overview
11.7.3 SciClone Pharmaceuticals Long Chain Modified Peptide Drugs Introduction
11.7.4 SciClone Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.7.5 SciClone Pharmaceuticals Recent Development
11.8 Sinopep Allsino Bio Pharmaceutical
11.8.1 Sinopep Allsino Bio Pharmaceutical Company Details
11.8.2 Sinopep Allsino Bio Pharmaceutical Business Overview
11.8.3 Sinopep Allsino Bio Pharmaceutical Long Chain Modified Peptide Drugs Introduction
11.8.4 Sinopep Allsino Bio Pharmaceutical Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.8.5 Sinopep Allsino Bio Pharmaceutical Recent Development
11.9 Takeda
11.9.1 Takeda Company Details
11.9.2 Takeda Business Overview
11.9.3 Takeda Long Chain Modified Peptide Drugs Introduction
11.9.4 Takeda Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.9.5 Takeda Recent Development
11.10 Roche
11.10.1 Roche Company Details
11.10.2 Roche Business Overview
11.10.3 Roche Long Chain Modified Peptide Drugs Introduction
11.10.4 Roche Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.10.5 Roche Recent Development
11.11 Sanofi
11.11.1 Sanofi Company Details
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Long Chain Modified Peptide Drugs Introduction
11.11.4 Sanofi Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.11.5 Sanofi Recent Development
11.12 Ambio Pharmaceuticals
11.12.1 Ambio Pharmaceuticals Company Details
11.12.2 Ambio Pharmaceuticals Business Overview
11.12.3 Ambio Pharmaceuticals Long Chain Modified Peptide Drugs Introduction
11.12.4 Ambio Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.12.5 Ambio Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Long Chain Modified Peptide Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Hormone Peptide Drugs
Table 3. Key Players of Immunomodulatory Peptide Drugs
Table 4. Key Players of Vasoactive Peptide Drugs
Table 5. Key Players of Others
Table 6. Global Long Chain Modified Peptide Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Long Chain Modified Peptide Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Long Chain Modified Peptide Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Long Chain Modified Peptide Drugs Market Share by Region (2020-2025)
Table 10. Global Long Chain Modified Peptide Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Long Chain Modified Peptide Drugs Market Share by Region (2026-2031)
Table 12. Long Chain Modified Peptide Drugs Market Trends
Table 13. Long Chain Modified Peptide Drugs Market Drivers
Table 14. Long Chain Modified Peptide Drugs Market Challenges
Table 15. Long Chain Modified Peptide Drugs Market Restraints
Table 16. Global Long Chain Modified Peptide Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Long Chain Modified Peptide Drugs Market Share by Players (2020-2025)
Table 18. Global Top Long Chain Modified Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long Chain Modified Peptide Drugs as of 2024)
Table 19. Ranking of Global Top Long Chain Modified Peptide Drugs Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Long Chain Modified Peptide Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Long Chain Modified Peptide Drugs, Headquarters and Area Served
Table 22. Global Key Players of Long Chain Modified Peptide Drugs, Product and Application
Table 23. Global Key Players of Long Chain Modified Peptide Drugs, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Long Chain Modified Peptide Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Long Chain Modified Peptide Drugs Revenue Market Share by Type (2020-2025)
Table 27. Global Long Chain Modified Peptide Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Long Chain Modified Peptide Drugs Revenue Market Share by Type (2026-2031)
Table 29. Global Long Chain Modified Peptide Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Long Chain Modified Peptide Drugs Revenue Market Share by Application (2020-2025)
Table 31. Global Long Chain Modified Peptide Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Long Chain Modified Peptide Drugs Revenue Market Share by Application (2026-2031)
Table 33. North America Long Chain Modified Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Long Chain Modified Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Long Chain Modified Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Long Chain Modified Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Long Chain Modified Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Long Chain Modified Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Long Chain Modified Peptide Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Long Chain Modified Peptide Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Long Chain Modified Peptide Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Long Chain Modified Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Long Chain Modified Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Long Chain Modified Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Long Chain Modified Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Long Chain Modified Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Long Chain Modified Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 48. Novartis Company Details
Table 49. Novartis Business Overview
Table 50. Novartis Long Chain Modified Peptide Drugs Product
Table 51. Novartis Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 52. Novartis Recent Development
Table 53. Merck Serono Company Details
Table 54. Merck Serono Business Overview
Table 55. Merck Serono Long Chain Modified Peptide Drugs Product
Table 56. Merck Serono Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 57. Merck Serono Recent Development
Table 58. Ferring Pharmaceuticals Company Details
Table 59. Ferring Pharmaceuticals Business Overview
Table 60. Ferring Pharmaceuticals Long Chain Modified Peptide Drugs Product
Table 61. Ferring Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 62. Ferring Pharmaceuticals Recent Development
Table 63. lpsen PHarma Biotech Company Details
Table 64. lpsen PHarma Biotech Business Overview
Table 65. lpsen PHarma Biotech Long Chain Modified Peptide Drugs Product
Table 66. lpsen PHarma Biotech Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 67. lpsen PHarma Biotech Recent Development
Table 68. Lilly Company Details
Table 69. Lilly Business Overview
Table 70. Lilly Long Chain Modified Peptide Drugs Product
Table 71. Lilly Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 72. Lilly Recent Development
Table 73. AstraZeneca Company Details
Table 74. AstraZeneca Business Overview
Table 75. AstraZeneca Long Chain Modified Peptide Drugs Product
Table 76. AstraZeneca Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 77. AstraZeneca Recent Development
Table 78. SciClone Pharmaceuticals Company Details
Table 79. SciClone Pharmaceuticals Business Overview
Table 80. SciClone Pharmaceuticals Long Chain Modified Peptide Drugs Product
Table 81. SciClone Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 82. SciClone Pharmaceuticals Recent Development
Table 83. Sinopep Allsino Bio Pharmaceutical Company Details
Table 84. Sinopep Allsino Bio Pharmaceutical Business Overview
Table 85. Sinopep Allsino Bio Pharmaceutical Long Chain Modified Peptide Drugs Product
Table 86. Sinopep Allsino Bio Pharmaceutical Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 87. Sinopep Allsino Bio Pharmaceutical Recent Development
Table 88. Takeda Company Details
Table 89. Takeda Business Overview
Table 90. Takeda Long Chain Modified Peptide Drugs Product
Table 91. Takeda Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 92. Takeda Recent Development
Table 93. Roche Company Details
Table 94. Roche Business Overview
Table 95. Roche Long Chain Modified Peptide Drugs Product
Table 96. Roche Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 97. Roche Recent Development
Table 98. Sanofi Company Details
Table 99. Sanofi Business Overview
Table 100. Sanofi Long Chain Modified Peptide Drugs Product
Table 101. Sanofi Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 102. Sanofi Recent Development
Table 103. Ambio Pharmaceuticals Company Details
Table 104. Ambio Pharmaceuticals Business Overview
Table 105. Ambio Pharmaceuticals Long Chain Modified Peptide Drugs Product
Table 106. Ambio Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 107. Ambio Pharmaceuticals Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
Table 111. Authors List of This Report
List of Figures
Figure 1. Long Chain Modified Peptide Drugs Picture
Figure 2. Global Long Chain Modified Peptide Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Long Chain Modified Peptide Drugs Market Share by Type: 2024 VS 2031
Figure 4. Hormone Peptide Drugs Features
Figure 5. Immunomodulatory Peptide Drugs Features
Figure 6. Vasoactive Peptide Drugs Features
Figure 7. Others Features
Figure 8. Global Long Chain Modified Peptide Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Long Chain Modified Peptide Drugs Market Share by Application: 2024 VS 2031
Figure 10. Intravenous Injection Case Studies
Figure 11. Intramuscular Injection Case Studies
Figure 12. Hypodermic Injection Case Studies
Figure 13. Others Case Studies
Figure 14. Long Chain Modified Peptide Drugs Report Years Considered
Figure 15. Global Long Chain Modified Peptide Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Long Chain Modified Peptide Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Long Chain Modified Peptide Drugs Market Share by Region: 2024 VS 2031
Figure 18. Global Long Chain Modified Peptide Drugs Market Share by Players in 2024
Figure 19. Global Top Long Chain Modified Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long Chain Modified Peptide Drugs as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Long Chain Modified Peptide Drugs Revenue in 2024
Figure 21. North America Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Long Chain Modified Peptide Drugs Market Share by Country (2020-2031)
Figure 23. United States Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Long Chain Modified Peptide Drugs Market Share by Country (2020-2031)
Figure 27. Germany Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Long Chain Modified Peptide Drugs Market Share by Region (2020-2031)
Figure 35. China Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Long Chain Modified Peptide Drugs Market Share by Country (2020-2031)
Figure 43. Mexico Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Long Chain Modified Peptide Drugs Market Share by Country (2020-2031)
Figure 47. Turkey Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Novartis Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 51. Merck Serono Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 52. Ferring Pharmaceuticals Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 53. lpsen PHarma Biotech Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 54. Lilly Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 55. AstraZeneca Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 56. SciClone Pharmaceuticals Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 57. Sinopep Allsino Bio Pharmaceutical Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 58. Takeda Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 59. Roche Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 60. Sanofi Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 61. Ambio Pharmaceuticals Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Table 1. Global Long Chain Modified Peptide Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Hormone Peptide Drugs
Table 3. Key Players of Immunomodulatory Peptide Drugs
Table 4. Key Players of Vasoactive Peptide Drugs
Table 5. Key Players of Others
Table 6. Global Long Chain Modified Peptide Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Long Chain Modified Peptide Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Long Chain Modified Peptide Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Long Chain Modified Peptide Drugs Market Share by Region (2020-2025)
Table 10. Global Long Chain Modified Peptide Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Long Chain Modified Peptide Drugs Market Share by Region (2026-2031)
Table 12. Long Chain Modified Peptide Drugs Market Trends
Table 13. Long Chain Modified Peptide Drugs Market Drivers
Table 14. Long Chain Modified Peptide Drugs Market Challenges
Table 15. Long Chain Modified Peptide Drugs Market Restraints
Table 16. Global Long Chain Modified Peptide Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Long Chain Modified Peptide Drugs Market Share by Players (2020-2025)
Table 18. Global Top Long Chain Modified Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long Chain Modified Peptide Drugs as of 2024)
Table 19. Ranking of Global Top Long Chain Modified Peptide Drugs Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Long Chain Modified Peptide Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Long Chain Modified Peptide Drugs, Headquarters and Area Served
Table 22. Global Key Players of Long Chain Modified Peptide Drugs, Product and Application
Table 23. Global Key Players of Long Chain Modified Peptide Drugs, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Long Chain Modified Peptide Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Long Chain Modified Peptide Drugs Revenue Market Share by Type (2020-2025)
Table 27. Global Long Chain Modified Peptide Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Long Chain Modified Peptide Drugs Revenue Market Share by Type (2026-2031)
Table 29. Global Long Chain Modified Peptide Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Long Chain Modified Peptide Drugs Revenue Market Share by Application (2020-2025)
Table 31. Global Long Chain Modified Peptide Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Long Chain Modified Peptide Drugs Revenue Market Share by Application (2026-2031)
Table 33. North America Long Chain Modified Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Long Chain Modified Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Long Chain Modified Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Long Chain Modified Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Long Chain Modified Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Long Chain Modified Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Long Chain Modified Peptide Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Long Chain Modified Peptide Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Long Chain Modified Peptide Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Long Chain Modified Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Long Chain Modified Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Long Chain Modified Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Long Chain Modified Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Long Chain Modified Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Long Chain Modified Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 48. Novartis Company Details
Table 49. Novartis Business Overview
Table 50. Novartis Long Chain Modified Peptide Drugs Product
Table 51. Novartis Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 52. Novartis Recent Development
Table 53. Merck Serono Company Details
Table 54. Merck Serono Business Overview
Table 55. Merck Serono Long Chain Modified Peptide Drugs Product
Table 56. Merck Serono Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 57. Merck Serono Recent Development
Table 58. Ferring Pharmaceuticals Company Details
Table 59. Ferring Pharmaceuticals Business Overview
Table 60. Ferring Pharmaceuticals Long Chain Modified Peptide Drugs Product
Table 61. Ferring Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 62. Ferring Pharmaceuticals Recent Development
Table 63. lpsen PHarma Biotech Company Details
Table 64. lpsen PHarma Biotech Business Overview
Table 65. lpsen PHarma Biotech Long Chain Modified Peptide Drugs Product
Table 66. lpsen PHarma Biotech Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 67. lpsen PHarma Biotech Recent Development
Table 68. Lilly Company Details
Table 69. Lilly Business Overview
Table 70. Lilly Long Chain Modified Peptide Drugs Product
Table 71. Lilly Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 72. Lilly Recent Development
Table 73. AstraZeneca Company Details
Table 74. AstraZeneca Business Overview
Table 75. AstraZeneca Long Chain Modified Peptide Drugs Product
Table 76. AstraZeneca Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 77. AstraZeneca Recent Development
Table 78. SciClone Pharmaceuticals Company Details
Table 79. SciClone Pharmaceuticals Business Overview
Table 80. SciClone Pharmaceuticals Long Chain Modified Peptide Drugs Product
Table 81. SciClone Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 82. SciClone Pharmaceuticals Recent Development
Table 83. Sinopep Allsino Bio Pharmaceutical Company Details
Table 84. Sinopep Allsino Bio Pharmaceutical Business Overview
Table 85. Sinopep Allsino Bio Pharmaceutical Long Chain Modified Peptide Drugs Product
Table 86. Sinopep Allsino Bio Pharmaceutical Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 87. Sinopep Allsino Bio Pharmaceutical Recent Development
Table 88. Takeda Company Details
Table 89. Takeda Business Overview
Table 90. Takeda Long Chain Modified Peptide Drugs Product
Table 91. Takeda Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 92. Takeda Recent Development
Table 93. Roche Company Details
Table 94. Roche Business Overview
Table 95. Roche Long Chain Modified Peptide Drugs Product
Table 96. Roche Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 97. Roche Recent Development
Table 98. Sanofi Company Details
Table 99. Sanofi Business Overview
Table 100. Sanofi Long Chain Modified Peptide Drugs Product
Table 101. Sanofi Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 102. Sanofi Recent Development
Table 103. Ambio Pharmaceuticals Company Details
Table 104. Ambio Pharmaceuticals Business Overview
Table 105. Ambio Pharmaceuticals Long Chain Modified Peptide Drugs Product
Table 106. Ambio Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
Table 107. Ambio Pharmaceuticals Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
Table 111. Authors List of This Report
List of Figures
Figure 1. Long Chain Modified Peptide Drugs Picture
Figure 2. Global Long Chain Modified Peptide Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Long Chain Modified Peptide Drugs Market Share by Type: 2024 VS 2031
Figure 4. Hormone Peptide Drugs Features
Figure 5. Immunomodulatory Peptide Drugs Features
Figure 6. Vasoactive Peptide Drugs Features
Figure 7. Others Features
Figure 8. Global Long Chain Modified Peptide Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Long Chain Modified Peptide Drugs Market Share by Application: 2024 VS 2031
Figure 10. Intravenous Injection Case Studies
Figure 11. Intramuscular Injection Case Studies
Figure 12. Hypodermic Injection Case Studies
Figure 13. Others Case Studies
Figure 14. Long Chain Modified Peptide Drugs Report Years Considered
Figure 15. Global Long Chain Modified Peptide Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Long Chain Modified Peptide Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Long Chain Modified Peptide Drugs Market Share by Region: 2024 VS 2031
Figure 18. Global Long Chain Modified Peptide Drugs Market Share by Players in 2024
Figure 19. Global Top Long Chain Modified Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long Chain Modified Peptide Drugs as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Long Chain Modified Peptide Drugs Revenue in 2024
Figure 21. North America Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Long Chain Modified Peptide Drugs Market Share by Country (2020-2031)
Figure 23. United States Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Long Chain Modified Peptide Drugs Market Share by Country (2020-2031)
Figure 27. Germany Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Long Chain Modified Peptide Drugs Market Share by Region (2020-2031)
Figure 35. China Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Long Chain Modified Peptide Drugs Market Share by Country (2020-2031)
Figure 43. Mexico Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Long Chain Modified Peptide Drugs Market Share by Country (2020-2031)
Figure 47. Turkey Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Novartis Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 51. Merck Serono Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 52. Ferring Pharmaceuticals Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 53. lpsen PHarma Biotech Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 54. Lilly Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 55. AstraZeneca Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 56. SciClone Pharmaceuticals Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 57. Sinopep Allsino Bio Pharmaceutical Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 58. Takeda Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 59. Roche Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 60. Sanofi Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 61. Ambio Pharmaceuticals Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Household Embroidery Machines Market Research Report 2025
Jul 18, 25
Global Residential Electric Underfloor Heating Market Research Report 2025
Jul 18, 25
Global Commercial Electric Underfloor Heating Market Research Report 2025
Jul 18, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232